Nurix Therapeutics, Inc.
For the period ended Aug 31, 2025. Filed Oct 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 31, 2025 · Filed Oct 9, 2025
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended August 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(186,236) | $(135,020) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 6,620 | 6,769 |
| Stock-based compensation | 28,879 | 25,421 |
| Net accretion of discount on marketable securities | (8,455) | (7,795) |
| Amortization of operating lease right-of-use assets | 7,605 | 5,356 |
| Other | — | 286 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (4,945) | 767 |
| Accounts payable | (3,655) | (2,376) |
| Deferred revenue | (23,403) | (15,265) |
| Operating lease liabilities | (4,311) | (4,768) |
| Accrued expenses and other current liabilities | 6,268 | 2,792 |
| Net cash used in operating activities | (181,633) | (123,833) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (281,350) | (409,738) |
| Maturities of marketable securities | 437,728 | 300,010 |
| Purchases of property and equipment | (8,871) | (7,168) |
| Net cash provided by (used in) investing activities | 147,507 | (116,896) |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options | 405 | 3,606 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,229 | 2,132 |
| Proceeds from issuances of common stock and pre-funded warrants in equity financing, net of issuance costs | — | 188,732 |
| Proceeds from issuances of common stock in “at the market” financing, net of issuance costs | — | 90,691 |
| Repurchase of unvested early exercised stock options | — | (15) |
| Net cash provided by financing activities | 2,634 | 285,146 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (31,492) | 44,417 |
| Cash, cash equivalents and restricted cash at beginning of period | 110,898 | 55,528 |
| Cash, cash equivalents and restricted cash at end of period | $79,406 | $99,945 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities | $2,120 | $483 |
| Right-of-use assets recognized in exchange for lease obligations | $32,494 | $1,297 |
| Deferred issuance costs included in accrued expenses and other current liabilities | $— | $156 |
| Deferred issuance costs recognized related to the “at the market” financing | $— | $242 |
| Vesting of early exercised stock options | $— | $33 |
| As of August 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $78,438 | $99,044 |
| Restricted cash | 968 | 901 |
| Total cash, cash equivalents and restricted cash | $79,406 | $99,945 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.